<

 
Data updated 2025-04-25 00:05:00
Translation DK > English
Need help for the searches?
[DISPLAY PATENT]
 
Choose application no.
 
Application no. and date20728258.3 (espacenet)  (Federated)  (European Patent Register), 20200424
Patent/reg. no. and dateDK/EP 3959235, 20230726
Publication date20220302
Priority no. and dateUS 201962839455 P, 20190426, US 202063005041 P, 20200403
EP pub. no. and date EP 3959235 20220302
Effective date
Applicant/ownerAllogene Therapeutics, Inc., 210 E. Grand Avenue
South San Francisco, CA 94080, US
Applicant ref. no.1666913
InventorPERTEL, Thomas Charles, c/o Allogene Therapeutcis, Inc. 210 E. Grand
Avenue
South San Francisco, California 94080, US,
SASU, Barbra Johnson, c/o Allogene Therapeutics, Inc. 210 E. Grand
Avenue
South San Francisco, California 94080, US,
LEONARD, Mark W., c/o Allogene Therapeutics, Inc. 210 E. Grand
Avenue
South San Francisco, California 94080, US
RepresentativeRWS Group, RWS Compass House Vanwall Business Park, Vanwall Road Maidenhead, Berkshire SL6 4UB , GB
Opponent
IPC ClassA61K 31/505 (2006.01) , C07K 14/725 (2006.01) 
TitleRITUXIMAB-RESISTENTE KIMÆRE ANTIGENRECEPTORER OG ANVENDELSER DERAF
Int. application no.US2020029775
Int. publication no.WO2020219848
Related patent (certificate)
StatusRettet DK/EP patent
Pædiatrisk forlængelse-
Udløbsdato for pædiatrisk forlængelse-

 
Home | Danish Patent and Trademark Office, Helgeshøj Allé 81, 2630 Tåstrup, Denmark Tel.: +45 4350 8000, email | Contact